Navigation Links
IIIb in Medical News

New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography

...rgeted agent far more common in the US than in Europe. "While chemotherapy doublets remain the standard regimen for first-line treatment of stage iiib and IV NSCLC, there are substantial differences among regions in the doublets most often chosen and whether a targeted agent is concurrently administe...

Competing With Botox - What Is On the Horizon?

...cluding pre and post procedure pictures and a broad outline of the design of the study. He will show monthly pictures and data of patients from Phase iiib (closed out at 12 months) and IIIC (15 months into a 3-year treatment period) of the study. Reloxin: Dr. Z. Paul Lorenc, a plastic surgeon wi...

Master molecular switch may prevent the spread of cancer cells to distant sites in the body

...wo forms, one called IIIb, which is expressed in epithelial cells and IIIc, which is expressed in mesenchymal cells. The protein that is made from the iiib form interacts with factors outside the cell that promote the epithelial cell behavior, that is to remain stationary. When the IIIc form is aberrantly...

PET/CT may improve prognosis for patients with inflammatory breast cancer

...tends to grow more quickly and aggressively than the more common types of breast cancer. Upon diagnosis, it is already considered to be at least stage iiib (locally advanced) and even stage IV if it has spread to distant parts of the body. Because of this, IBC has been harder to successfully treat than ot...

Alfacell Reports Financial Results for First Quarter of Fiscal 2009

...support its activities into the fourth quarter of fiscal year 2009. Clinical/Regulatory Update Alfacell has completed a confirmatory Phase iiib clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events t...

Novel 4-drug combination proves safe for lung cancer treatment

...st survival benefit when Erbitux is combined with chemotherapy. Between August 2006 and September 2007, the large Phase II study enrolled 110 Stage iiib or IV non-small cell lung cancer patients, 99 of whom were able to be evaluated. Patients received six cycles of the four-drug regimen, and as mainten...

Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis

...with relapsing-remitting multiple sclerosis." The IMPROVE study is a two-arm, randomized, double-blind, controlled, multicenter, international Phase iiib study to evaluate the efficacy, safety and tolerability of the new formulation of Rebif(R) in patients with RRMS according to the revised McDonald cri...

Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer

... III, randomized study compared the overall survival between pemetrexed+cisplatin versus gemcitabine+cisplatin in 1,725 chemonaive patients with stage iiib or IV NSCLC who also exhibited a performance status of 0-1. Patients on the pemetrexed arm (n = 862) were treated with pemetrexed (500 mg/m2) and cisp...

Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients

... infestations (2 percent). No unexpected safety concerns were identified during this study. About WELCOME The WELCOME study is a 539 patient Phase iiib multicenter 26-Week trial Evaluating the clinical benefit and tolerability of certoLizumab pegol induCtiOn and Maintenance in patients suffering from ...

Gene Signature May Predict Recurrence of Lung Cancer

... regimens starting as little as one month after surgery. Twenty individuals newly diagnosed with and who had undergone surgery for Stage I to Stage iiib lung cancer were asked to exercise three times a week for one hour at a time on stationary bikes. After 14 weeks, participants reported being less tir...
IIIb in Medical Technology

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer PARSIPPANY, N.J., April 27 /PRNewswire/ -- Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (G...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL ) reported that the preliminary statistical a...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

- Company to Host Conference Call/Webcast at 8:30 a.m. EDT on May 29 - SOMERSET, N.J., May 28 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound,...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control and Reducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC, in conjunction with its commercialization partner S2 Therapeutics, Inc., reported today the results of its Phase IIIb cl...

Alfacell Provides Shareholder Update

...and our valuable compounds realize their full potential. As you are aware, we did not meet our primary endpoint of overall survival in our Phase iiib clinical trial in patients suffering from unresectable malignant mesothelioma (UMM). We did however; achieve statistical significance with a subgroup ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...ctive R andomized study on the antiproliferative efficacy of O ctreotide LAR in patients with metastatic neuroendocrine MID gut tumors), is a Phase iiib study conducted at 18 sites in Germany to evaluate the antitumor effect of Sandostatin LAR in patients with midgut NET. The study included 85 patients...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...tumor from growing. The PROMID study included only patients with well-differentiated metastatic midgut tumors. About PROMID PROMID is a Phase iiib study conducted at 18 sites in Germany to evaluate the antitumor effect of Sandostatin LAR in patients with NETs. The study included 85 patients who w...

Alfacell Provides ONCONASE(R) NDA Submission Update

... meeting. As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase iiib clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However...

NovaRx Appoints Industry Veteran as President and COO

...lized in that Phase II trial to treat advanced stage NSCLC patients (stages iiib and IV) who had received zero to five prior chemotherapies, demonstrated a ...vival. Typical two year survival for stage IV patients is 5% and for stage iiib is 10% on average. Currently, 59% of the patients who received Lucanix(R) ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

...ith Crohn's disease. WELCOME Study (Abstract #P283) Data from the Phase iiib WELCOME study showed that 39 percent of patients who responded to CIMZIA tr...ologics studied. About WELCOME The WELCOME study is a 539 patient Phase iiib multicenter 26-Week trial Evaluating the clinical benefit and tolerability ...
IIIb in Medical Products

Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring

Features:... Corrects for the valvular insufficiency associated with Type iiib mitral regurgitation. Decreased anteroposterior (AP) distance increases leaflet coaptation. Asymmetric 3-D reduced P2-P3 curvature design comp...
Company:Edwards Lifesciences Corporation
IIIb in Biological News

Living view in animals shows how cells decide to make proteins

...the scientists could track whether intronic silencers were chopping out the iiib exon -- and if so, in which tissues and organs -- or whether other types of...ocesses," Bonano said. For example, a cell’s decision to include exon iiib is critical because the exon’s presence or absence determines which variant...
IIIb in Biological Technology

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

...ued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage iiib NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

...ured by UCB, was approved by the U.S. Food and Drug Administration on April 22, 2008. About WELCOME The WELCOME study is a 539 patient Phase iiib multicenter 26- W eek trial E valuating the clinical benefit and tolerability of certo L izumab pegol indu C ti O n and M aintenance in patients suf...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...ncothyreon. "These patients were treated as part of the randomized Phase 2b trial conducted by Oncothyreon, in which the subset of patients with Stage iiib locoregional disease who received Stimuvax had a median survival of 30.6 months compared with 13.3 months for similar patients who did not receive the...

BioVex Raises $40 Million in First Close of Series F Financing

...se III study will also enroll previously treated patients with unresectable Stage IIIc and Stage IV disease using OncoVEX GM-CSF as monotherapy. Stage iiib patients will also be eligible. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistic...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... Cancer Phase 1/2 Study Design with Updated Results as of January 23, 2009 This single-arm, open-label study enrolled 81 patients with Stage iiib (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination with a standard first-line NSCLC chemotherapy regimen that in...

Alfacell Provides ONCONASE(R) NDA Submission Update

...itting a NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase iiib clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However...

Alfacell Receives Going Concern Audit Opinion

...nabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to a recently completed Phase iiib study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visi...

Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results

...luding the U.S. license agreement with Strativa and completion of the Phase iiib clinical trial for ONCONASE in UMM. In fiscal 2009, we plan to complete the... other life-threatening diseases. In addition to a recently completed Phase iiib study in malignant mesothelioma, Alfacell is currently planning for Phase I...

NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients

...t approximately 90 clinical sites in the U.S., Canada, India, and Europe. In a Phase II clinical trial, two-year survival among patients with stages iiib and IV disease who received Lucanix(R) was significantly longer than that of individuals being treated with the current standard of care. A second, in...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

...nabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to a recently completed Phase iiib study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visi...
Other Tags
(Date:12/15/2014)... a leading mobile app development company , custom ... which allows users to keep track of wines they ... right wine. At the center of WineMatch is ... wine information. All this information is assembled to help ... are close counterparts to one another are called Matches. ...
(Date:12/15/2014)... 2014 Health Dialog, a leading ... that it has received Patient Oriented Accreditation from ... its Disease Management (DM) Programs for asthma, congestive ... heart disease and diabetes. This marks the 12th ... Dialog’s Disease Management (DM) Programs, reaffirming Health Dialog’s ...
(Date:12/15/2014)... SUNDAY, Dec. 14, 2014 (HealthDay News) -- Expert pilots ... which explains why they make better decisions during landings, ... the most difficult techniques for pilots to master, and ... of fatal crashes occur during final approach and landing. ... pilots and 12 moderately experienced pilots while they were ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Kathy McAfee, ... prestigious Women World Awards in the category of Best ... gold award for her weekly career blog Networking ... advice to help professionals elevate their talent and influence ... blog, named after her book Networking Ahead for Business, ...
(Date:12/15/2014)... Portland, OR (PRWEB) December 15, 2014 ... NAIRO seeks to bring attention to restrictive state ... new position paper on this important area of ... State Laws Can Compromise the Integrity of Independent ... quality and access of independent peer review determinations ...
Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
Other Contents